Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

Core Insights - Axsome Therapeutics reported a quarterly loss of $0.80 per share, which was better than the Zacks Consensus Estimate of a loss of$1.26, representing an earnings surprise of 36.51% [1] - The company achieved revenues of $121.46 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 1.66$75 million in the same quarter last year [2] - Axsome has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Financial Performance - The company has shown a loss improvement from $1.09 per share a year ago to the current loss of$0.80 per share [1] - Axsome's stock has increased by approximately 32.6% since the beginning of the year, contrasting with a -3.3% decline in the S&P 500 [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$1 on revenues of$139.97 million, and for the current fiscal year, it is -$2.72 on revenues of$616.42 million [7] - The Zacks Rank for Axsome is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Axsome belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Apellis Pharmaceuticals, is expected to report a quarterly loss of $0.36 per share, reflecting a year-over-year change of +33.3% [9]